27.97
price down icon4.23%   -1.235
after-market Dopo l'orario di chiusura: 28.36 0.39 +1.39%
loading
Precedente Chiudi:
$29.20
Aprire:
$28.55
Volume 24 ore:
1.14M
Relative Volume:
0.40
Capitalizzazione di mercato:
$3.49B
Reddito:
$22.12M
Utile/perdita netta:
$-245.15M
Rapporto P/E:
-7.2563
EPS:
-3.8546
Flusso di cassa netto:
$-373.40M
1 W Prestazione:
+5.39%
1M Prestazione:
+7.33%
6M Prestazione:
+534.24%
1 anno Prestazione:
+445.22%
Intervallo 1D:
Value
$27.82
$28.92
Intervallo di 1 settimana:
Value
$25.70
$30.60
Portata 52W:
Value
$2.7601
$30.60

Alumis Inc Stock (ALMS) Company Profile

Name
Nome
Alumis Inc
Name
Telefono
650-231-6625
Name
Indirizzo
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Name
Dipendente
233
Name
Cinguettio
Name
Prossima data di guadagno
Name
Ultimi documenti SEC
Name
ALMS's Discussions on Twitter

Compare ALMS vs VRTX, REGN, ARGX, ALNY, ONC

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
ALMS
Alumis Inc
27.97 3.64B 22.12M -245.15M -373.40M -3.8546
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
476.90 119.21B 12.07B 3.95B 3.19B 15.33
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
779.67 82.71B 14.34B 4.50B 3.77B 41.56
Biotechnology icon
ARGX
Argen X Se Adr
844.41 52.43B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
336.19 45.01B 3.71B 313.75M 465.38M 2.2571
Biotechnology icon
ONC
Beone Medicines Ltd Adr
362.14 39.23B 4.98B 69.60M 525.67M 0.5198

Alumis Inc Stock (ALMS) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2026-01-21 Iniziato Chardan Capital Markets Buy
2025-07-25 Iniziato Wells Fargo Overweight
2025-06-10 Ripresa Guggenheim Buy
2025-01-30 Iniziato Oppenheimer Outperform
2024-10-31 Iniziato Robert W. Baird Outperform
2024-10-17 Iniziato H.C. Wainwright Buy
2024-07-23 Iniziato Cantor Fitzgerald Overweight
2024-07-23 Iniziato Guggenheim Buy
2024-07-23 Iniziato Leerink Partners Outperform
2024-07-23 Iniziato Morgan Stanley Overweight
Mostra tutto

Alumis Inc Borsa (ALMS) Ultime notizie

pulisher
Feb 20, 2026

A | What is Alumis Inc.'s debt-to-equity ratio2025 Macro Impact & Fast Moving Trade Plans - mfd.ru

Feb 20, 2026
pulisher
Feb 20, 2026

Big Picture: Is Alumis Inc in a consolidation phaseWeekly Trend Report & Long-Term Growth Plans - baoquankhu1.vn

Feb 20, 2026
pulisher
Feb 20, 2026

Alumis Inc stock hits all-time high at 28.34 USD By Investing.com - Investing.com India

Feb 20, 2026
pulisher
Feb 19, 2026

Alumis (NASDAQ:ALMS) Sets New 52-Week HighStill a Buy? - MarketBeat

Feb 19, 2026
pulisher
Feb 19, 2026

Alumis Inc stock hits all-time high at 28.34 USD - Investing.com

Feb 19, 2026
pulisher
Feb 19, 2026

Alumis Inc. (ALMS): Investor Outlook Reveals 35% Upside Potential In Biotech Sector - DirectorsTalk Interviews

Feb 19, 2026
pulisher
Feb 18, 2026

Risk Hedge: Is Alumis Inc gaining market shareJuly 2025 Retail & Technical Pattern Based Buy Signals - baoquankhu1.vn

Feb 18, 2026
pulisher
Feb 17, 2026

Huge insider buying now at this insurance giant and 2 biotechs - MSN

Feb 17, 2026
pulisher
Feb 16, 2026

Alumis Stock: Key Catalysts on the Horizon for 2026 - AD HOC NEWS

Feb 16, 2026
pulisher
Feb 16, 2026

Credit Industriel ET Commercial Sells 140,000 Shares of Alumis Inc. $ALMS - MarketBeat

Feb 16, 2026
pulisher
Feb 14, 2026

Why Alumis Inc. stock is trending among retail tradersJuly 2025 Fed Impact & Weekly High Conviction Trade Ideas - mfd.ru

Feb 14, 2026
pulisher
Feb 12, 2026

Can Alumis Inc. expand into new markets2025 Momentum Check & Short-Term Swing Trade Alerts - mfd.ru

Feb 12, 2026
pulisher
Feb 12, 2026

Alumis (NASDAQ:ALMS) Shares Up 7.2%Still a Buy? - MarketBeat

Feb 12, 2026
pulisher
Feb 12, 2026

Alumis Highlights Phase III Psoriasis Wins, NDA Timing, and Lupus Catalyst at Guggenheim Summit - MarketBeat

Feb 12, 2026
pulisher
Feb 11, 2026

Is Alumis Inc.’s growth already priced inPortfolio Growth Summary & Weekly Watchlist of Top Performers - mfd.ru

Feb 11, 2026
pulisher
Feb 10, 2026

Quarterly Risk: Is Alumis Inc in a consolidation phase2025 Price Action Summary & Growth Focused Entry Reports - baoquankhu1.vn

Feb 10, 2026
pulisher
Feb 09, 2026

Can Alumis Inc. ride the EV wave2025 Pullback Review & Weekly High Potential Stock Alerts - mfd.ru

Feb 09, 2026
pulisher
Feb 08, 2026

Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter. - AOL.com

Feb 08, 2026
pulisher
Feb 07, 2026

Alumis (ALMS) Valuation Check After Strong Multi‑Month Share Price Momentum - Yahoo Finance

Feb 07, 2026
pulisher
Feb 06, 2026

EPS Watch: Can Alumis Inc ride the EV waveWeekly Stock Analysis & Expert Approved Momentum Trade Ideas - baoquankhu1.vn

Feb 06, 2026
pulisher
Feb 06, 2026

Market Leaders: Will TWFG outperform the market in YEARTrade Analysis Report & High Win Rate Trade Alerts - baoquankhu1.vn

Feb 06, 2026
pulisher
Feb 06, 2026

Alumis Ownership Shifts As Shelf Filing And Conferences Shape Outlook - Sahm

Feb 06, 2026
pulisher
Feb 05, 2026

Alumis to Participate in Upcoming February Investor Conferences - The Manila Times

Feb 05, 2026
pulisher
Feb 04, 2026

Alumis Inc. (NASDAQ:ALMS) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Feb 04, 2026
pulisher
Feb 02, 2026

Alumis and ACELYRIN announce merger in all-stock deal - MSN

Feb 02, 2026
pulisher
Feb 02, 2026

Alumis (NASDAQ:ALMS) Stock Price Up 9.8%What's Next? - MarketBeat

Feb 02, 2026
pulisher
Feb 02, 2026

Alumis Inc stock (ALMS) jumps again on Nasdaq — here’s what’s driving the move and what comes next - TechStock²

Feb 02, 2026
pulisher
Feb 02, 2026

Why Alumis Inc. Stock Is Suddenly Powering Higher - TipRanks

Feb 02, 2026
pulisher
Jan 31, 2026

Chardan highlights Alumis’s (ALMS) potential after envudeucitinib hits all phase 3 endpoints in psoriasis trials - MSN

Jan 31, 2026
pulisher
Jan 30, 2026

Alumis Inc. (ALMS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Jan 30, 2026
pulisher
Jan 30, 2026

Top Small Cap Stocks To Watch NowJanuary 6th - MarketBeat

Jan 30, 2026
pulisher
Jan 30, 2026

Chardan Highlights Alumis's (ALMS) Potential After Envudeucitinib Hits All Phase 3 Endpoints in Psoriasis Trials - Finviz

Jan 30, 2026
pulisher
Jan 30, 2026

Chardan Highlights Alumis’s (ALMS) Potential After Envudeucitinib Hits All Phase 3 Endpoints in Psoriasis Trials - Insider Monkey

Jan 30, 2026
pulisher
Jan 30, 2026

Alumis Inc. (NASDAQ:ALMS) Short Interest Up 93.1% in January - MarketBeat

Jan 30, 2026
pulisher
Jan 29, 2026

Alumis stock hits all-time high at 27.28 USD By Investing.com - Investing.com Australia

Jan 29, 2026
pulisher
Jan 29, 2026

Alumis Inc. (ALMS) Stock Analysis: A Biotech Contender With A 34.43% Potential Upside - DirectorsTalk Interviews

Jan 29, 2026
pulisher
Jan 29, 2026

10 New Stocks on the Rise - Insider Monkey

Jan 29, 2026
pulisher
Jan 28, 2026

Alumis (NASDAQ:ALMS) Hits New 12-Month HighStill a Buy? - MarketBeat

Jan 28, 2026
pulisher
Jan 28, 2026

Alumis stock hits all-time high at 27.28 USD - Investing.com

Jan 28, 2026
pulisher
Jan 26, 2026

Alumis (NASDAQ:ALMS) Trading Up 6.4%Should You Buy? - MarketBeat

Jan 26, 2026
pulisher
Jan 26, 2026

Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib - AOL.com

Jan 26, 2026
pulisher
Jan 22, 2026

Alumis (NASDAQ:ALMS) Coverage Initiated by Analysts at Chardan Capital - MarketBeat

Jan 22, 2026
pulisher
Jan 21, 2026

Alumis stock reaches all-time high at 25.25 USD By Investing.com - Investing.com Australia

Jan 21, 2026
pulisher
Jan 21, 2026

This Crescent Biopharma Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga

Jan 21, 2026
pulisher
Jan 21, 2026

Chardan Capital initiates coverage on Alumis stock with Buy rating - Investing.com

Jan 21, 2026
pulisher
Jan 21, 2026

Chardan Capital initiates coverage on Alumis stock with Buy rating By Investing.com - Investing.com Nigeria

Jan 21, 2026

Alumis Inc Azioni (ALMS) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$49.87
price up icon 0.34%
$101.83
price down icon 0.89%
$101.32
price down icon 0.40%
$110.14
price down icon 0.25%
$164.91
price up icon 2.43%
biotechnology ONC
$362.14
price up icon 2.16%
Capitalizzazione:     |  Volume (24 ore):